429 related articles for article (PubMed ID: 23071695)
1. Serum microRNA-155 as a potential biomarker to track disease in breast cancer.
Sun Y; Wang M; Lin G; Sun S; Li X; Qi J; Li J
PLoS One; 2012; 7(10):e47003. PubMed ID: 23071695
[TBL] [Abstract][Full Text] [Related]
2. Thioredoxin 1 as a serum marker for breast cancer and its use in combination with CEA or CA15-3 for improving the sensitivity of breast cancer diagnoses.
Park BJ; Cha MK; Kim IH
BMC Res Notes; 2014 Jan; 7():7. PubMed ID: 24393391
[TBL] [Abstract][Full Text] [Related]
3. Diagnostic Value of Serum miR-182, miR-183, miR-210, and miR-126 Levels in Patients with Early-Stage Non-Small Cell Lung Cancer.
Zhu W; Zhou K; Zha Y; Chen D; He J; Ma H; Liu X; Le H; Zhang Y
PLoS One; 2016; 11(4):e0153046. PubMed ID: 27093275
[TBL] [Abstract][Full Text] [Related]
4. Plasma mammaglobin messenger RNA in breast cancer patients as an addition to serum tumor.
El-Attar NI; Gaefar HA
Egypt J Immunol; 2007; 14(2):111-21. PubMed ID: 20306663
[TBL] [Abstract][Full Text] [Related]
5. The Clinical Significance of sICAM-1 in Differentiating Benign Breast Lesions from Breast Cancer.
Chen C; Chen Q; Dong Y; Liu X
Ann Clin Lab Sci; 2020 Sep; 50(5):650-656. PubMed ID: 33067211
[TBL] [Abstract][Full Text] [Related]
6. The diagnostic value of serum tumor markers CEA, CA19-9, CA125, CA15-3, and TPS in metastatic breast cancer.
Wang W; Xu X; Tian B; Wang Y; Du L; Sun T; Shi Y; Zhao X; Jing J
Clin Chim Acta; 2017 Jul; 470():51-55. PubMed ID: 28457854
[TBL] [Abstract][Full Text] [Related]
7. Independent prognostic impact of preoperative serum carcinoembryonic antigen and cancer antigen 15-3 levels for early breast cancer subtypes.
Imamura M; Morimoto T; Nomura T; Michishita S; Nishimukai A; Higuchi T; Fujimoto Y; Miyagawa Y; Kira A; Murase K; Araki K; Takatsuka Y; Oh K; Masai Y; Akazawa K; Miyoshi Y
World J Surg Oncol; 2018 Feb; 16(1):26. PubMed ID: 29433529
[TBL] [Abstract][Full Text] [Related]
8. Serum circulating microRNA profiling for identification of potential breast cancer biomarkers.
Mar-Aguilar F; Mendoza-Ramírez JA; Malagón-Santiago I; Espino-Silva PK; Santuario-Facio SK; Ruiz-Flores P; Rodríguez-Padilla C; Reséndez-Pérez D
Dis Markers; 2013; 34(3):163-9. PubMed ID: 23334650
[TBL] [Abstract][Full Text] [Related]
9. Activated leukocyte cell adhesion molecule: a novel biomarker for breast cancer.
Kulasingam V; Zheng Y; Soosaipillai A; Leon AE; Gion M; Diamandis EP
Int J Cancer; 2009 Jul; 125(1):9-14. PubMed ID: 19322904
[TBL] [Abstract][Full Text] [Related]
10. Diagnostic Value of Serum Concentration and Integrity of Circulating Cell-Free DNA in Breast Cancer: A Comparative Study With CEA and CA15-3.
Tang Z; Li L; Shen L; Shen X; Ju S; Cong H
Lab Med; 2018 Oct; 49(4):323-328. PubMed ID: 29701836
[TBL] [Abstract][Full Text] [Related]
11. Serum miR-21 and miR-125b as markers predicting neoadjuvant chemotherapy response and prognosis in stage II/III breast cancer.
Liu B; Su F; Chen M; Li Y; Qi X; Xiao J; Li X; Liu X; Liang W; Zhang Y; Zhang J
Hum Pathol; 2017 Jun; 64():44-52. PubMed ID: 28412211
[TBL] [Abstract][Full Text] [Related]
12. The diagnostic power of circulating micro ribonucleic acid 34a in combination with cancer antigen 15-3 as a potential biomarker of breast cancer.
Raheem AR; Abdul-Rasheed OF; Al-Naqqash MA
Saudi Med J; 2019 Dec; 40(12):1218-1226. PubMed ID: 31828273
[TBL] [Abstract][Full Text] [Related]
13. Exosomal miR-1246 and miR-155 as predictive and prognostic biomarkers for trastuzumab-based therapy resistance in HER2-positive breast cancer.
Zhang Z; Zhang L; Yu G; Sun Z; Wang T; Tian X; Duan X; Zhang C
Cancer Chemother Pharmacol; 2020 Dec; 86(6):761-772. PubMed ID: 33068176
[TBL] [Abstract][Full Text] [Related]
14. HER-2 gene amplification, serum nucleosomes, CEA and CA15.3 tumor markers in breast cancer patients.
Zeiwar MM; Zaki SM; Mohammad LA; Zidan AA; El Nagar MR
Egypt J Immunol; 2007; 14(2):29-41. PubMed ID: 20306655
[TBL] [Abstract][Full Text] [Related]
15. Serum Tumor Marker Levels might have Little Significance in Evaluating Neoadjuvant Treatment Response in Locally Advanced Breast Cancer.
Wang YJ; Huang XY; Mo M; Li JW; Jia XQ; Shao ZM; Shen ZZ; Wu J; Liu GY
Asian Pac J Cancer Prev; 2015; 16(11):4603-8. PubMed ID: 26107211
[TBL] [Abstract][Full Text] [Related]
16. Circulating miR-338-5p is a potential diagnostic biomarker in colorectal cancer.
Bilegsaikhan E; Liu HN; Shen XZ; Liu TT
J Dig Dis; 2018 Jul; 19(7):404-410. PubMed ID: 29952077
[TBL] [Abstract][Full Text] [Related]
17. Serum overexpression of microRNA-10b in patients with bone metastatic primary breast cancer.
Zhao FL; Hu GD; Wang XF; Zhang XH; Zhang YK; Yu ZS
J Int Med Res; 2012; 40(3):859-66. PubMed ID: 22906258
[TBL] [Abstract][Full Text] [Related]
18. Decreased expression of miR-204 in plasma is associated with a poor prognosis in patients with non-small cell lung cancer.
Guo W; Zhang Y; Zhang Y; Shi Y; Xi J; Fan H; Xu S
Int J Mol Med; 2015 Dec; 36(6):1720-6. PubMed ID: 26497897
[TBL] [Abstract][Full Text] [Related]
19. Circulating microRNA-92a and microRNA-21 as novel minimally invasive biomarkers for primary breast cancer.
Si H; Sun X; Chen Y; Cao Y; Chen S; Wang H; Hu C
J Cancer Res Clin Oncol; 2013 Feb; 139(2):223-9. PubMed ID: 23052693
[TBL] [Abstract][Full Text] [Related]
20. Serum microRNA-135a-5p as an auxiliary diagnostic biomarker for colorectal cancer.
Wang Q; Zhang H; Shen X; Ju S
Ann Clin Biochem; 2017 Jan; 54(1):76-85. PubMed ID: 27126269
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
